Skip to main content

Table 4 Cost-effectiveness results: ERG revisions to company base case

From: Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Description Nab-Pac + Gem vs. Gem Nab-Pac + Gem vs. Gem + Cap Nab-Pac + Gem vs. FOLFIRINOX
Company original base case £46,657 Dominated Dominated
Company updated base case £46,932 Dominated Dominated
ERG corrected company base case £47,011 Dominated Dominated
 R1) HRs for Gem + Cap vs. Gem – £103,827 –
 R2) HRs for FOLFIRINOX vs. Gem £47,012 Dominated £3327
 R3) ERG drug-costing method £39,289 Dominated Dominated
 R4) TOT from CA046 trial £49,922 Dominated Dominated
 R5) Do not apply AE disutilities £46,994 Dominated Dominated
 R6) ERG OS £46,681 Dominated Dominated
 R7) ERG PFS £46,933 Dominated Dominated
ERG revised base case (R3, R4, R5, R6, R7) £41,250 – –
ERG revised base case (R1, R3, R4, R5, R6, R7) – £99,837 –
ERG revised base case (R2, R3, R4, R5, R6, R7) – – Dominated
  1. AE adverse event, ERG Evidence Review Group, FOLFIRINOX combination of oxaliplatin, irinotecan, leucovorin and fluorouracil, Gem gemcitabine, Gem + Cap gemcitabine in combination with capecitabine, HRs hazard ratios, Nab-Pac + Gem paclitaxel as albumin-bound nanoparticles in combination with gemcitabine, Nab-Pac + Gem paclitaxel as albumin-bound nanoparticles in combination with gemcitabine, PFS progression-free survival, OS overall survival, TOT time on treatment
Back to article page